R-ESHAP Regimen

R-ESHAP (Rituximab + Etoposide, Methylprednisolone, Cytarabine, Cisplatin)

• Indication:
  • Relapsed or refractory aggressive B-cell lymphomas, especially in fit, younger patients
  • Common salvage regimen prior to autologous stem cell transplant
• Eligible Patients:
  • Transplant-eligible patients with good organ function
  • Requires inpatient administration and close monitoring
• Pros:
  • High response rates in chemosensitive lymphomas
  • Effective option for second-line therapy in aggressive NHL
  • Broad cytotoxic coverage (etoposide + cytarabine + platinum)
• Key Toxicities:
  • Myelosuppression
  • Nephrotoxicity (cisplatin)
  • Neurotoxicity (especially from cytarabine)
  • Electrolyte disturbances, mucositis, risk of febrile neutropenia